WO2001017578A1 - Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb - Google Patents
Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb Download PDFInfo
- Publication number
- WO2001017578A1 WO2001017578A1 PCT/ES2000/000335 ES0000335W WO0117578A1 WO 2001017578 A1 WO2001017578 A1 WO 2001017578A1 ES 0000335 W ES0000335 W ES 0000335W WO 0117578 A1 WO0117578 A1 WO 0117578A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound according
- htb
- triflusal
- formula
- compound
- Prior art date
Links
- XUXJHBAJZQREDB-UHFFFAOYSA-N CCC(C)C(N)=O Chemical compound CCC(C)C(N)=O XUXJHBAJZQREDB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/30—Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0041—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/30—Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety
- C08F220/302—Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety and two or more oxygen atoms in the alcohol moiety
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
- C08F220/30—Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety
- C08F220/305—Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
- C08F220/306—Esters containing oxygen in addition to the carboxy oxygen containing aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and polyethylene oxide chain in the alcohol moiety
Definitions
- New biocompatible polymer systems carrying triflusal or HTB carrying triflusal or HTB.
- the present invention relates to a new series of biocompatible polymer systems, and more specifically to a new series of biocompatible polymer systems carrying triflusal or HTB.
- the invention also relates to a process for its preparation, as well as its applications, especially as coating of prostheses and other articles or devices that will be in contact with the blood during use.
- the application of synthetic materials in the field of cardiovascular surgery and especially in the reconstruction of the vascular system has constituted one of the great advances in this field.
- the materials used must not only have adequate physicochemical properties such as flexibility, hydrolytic stability and fatigue resistance, but it is essential that they have a good blood biocompatibility or hemocompatibility.
- the contact of prosthetic devices with blood flow leads to the deposition of plasma proteins on the surface of the material and to the activation of the coagulation cascade, which generates a thrombogenic surface.
- Triflusal whose chemical name is 2-acetyloxy-4-trifluoromethylbenzoic acid, is an inhibitor of platelet aggregation marketed for the treatment of thromboembolic diseases. his The main metabolite, known by the acronym HTB and chemical name 2- hydroxy-4-trifluoromethylbenzoic acid, also has a remarkable activity as a platelet antiaggregant. Both compounds are described in US 4,096,252.
- the present invention provides a new series of biocompatible polymeric derivatives carrying triflusal or HTB which, applied as a surface coating of prosthetic devices and other items that are in contact with the blood during use, improve their thrombogenic properties. Explanation of the invention.
- the object of the present invention is a polymeric compound of relative general formula I
- A represents a residue of a polymerizable monomer of the acrylic or vinyl type bearing triflusal or HTB, where the triflusal or HTB are linked to the rest of the monomer molecule through a covalent bond hydrolysable in vivo;
- B represents a residue of a second polymerizable monomer
- m and n indicate the molar fractions of monomers A and B in the polymer so that m + n is always 1 and m is always different from 0; and where the distribution of units A and B in the polymer is random.
- Another object of the present invention is a process for preparing a polymeric compound of formula I characterized in that it comprises the radical polymerization of a monomer A and optionally a second monomer B in the myn molar proportions, respectively, in the presence of a polymerization initiator , within a suitable solvent.
- the polymeric compounds of the present invention are useful for coating the surface of synthetic materials or of non-biological origin (which we will refer to jointly as non-biological materials throughout the present description) that will be in contact with the blood.
- the polymers of the present invention are carriers of triflusal or HTB, compounds with a remarkable antiaggregant activity, which are released through the hydrolysis of the covalent bond that binds them to the rest of the polymer system, the application of the polymers of the present invention on the surface of said non-biological materials improves the thrombogenic properties thereof.
- the polymeric compounds of the present invention can be used in principle to coat any article or device that has a surface that will be in contact with the blood during use, and especially to coat vascular prostheses, particularly those of small or medium caliber , as well as artificial heart valves and stents or vascular springs for application in arteriosclerosis processes. That is why it is also the object of the present invention to use a polymeric compound of formula I as a coating for non-biological materials, and especially as a coating for vascular prostheses, artificial heart valves and stents.
- Also object of the present invention are articles or devices comprising a surface of a non-biological material that will be in contact with the blood during use coated with a triflusal or HTB carrier polymer of formula I, and especially vascular prostheses , artificial heart valves and stents coated with a triflusal or HTB carrier polymer of formula I.
- the object of the present invention is also a process for preparing said articles or devices comprising coating the desired article or device with a triflusal or HTB carrier polymer of formula I.
- the triflusal or the HTBs are bound to the rest of the polymer system through hydrolysable covalent bonds.
- triflusal or HTB is released through the hydrolysis of these covalent bonds. That is why the polymeric compounds of the present invention can also be used as a controlled release system of triflusal or HTB and could therefore be useful for the treatment or prevention of all those diseases for which the triflusal or HTB are indicated. . It is therefore also the object of the present invention to use a polymeric compound of formula I as a controlled release system of triflusal or HTB, useful in the therapeutic field.
- a polymeric compound of formula I for the manufacture of a medicament for the treatment or prevention of the diseases for which the triflusal or the HTB is indicated and especially for the treatment or prevention of thromboembolic diseases
- the subject of the invention is also a pharmaceutical composition comprising a polymeric compound of formula I and one or more pharmaceutically acceptable excipients. Said compositions may be prepared following conventional procedures, well known to those skilled in the art.
- the residue of a polymerizable monomer is understood as the residue resulting from the polymerization of the corresponding monomer.
- the polymerizable monomer corresponding to B is N, N-dimethylacrylamide, in formula I B in fact represents the once polymerized residue of said monomer, as shown below:
- polymerizable monomer precursor B (residue of monomer already of B in polymerized formula I)
- a and B will be used throughout the present description to refer interchangeably to the polymerizable monomer or to the corresponding residue already polymerized within the polymer of formula I.
- A represents a residue of any polymerizable monomer of acrylic or vinyl type that is a carrier of triflusal or HTB.
- carrier it is understood that it contains the triflusal or HTB molecule bound to the rest of the acrylic or vinyl type through a covalent bond that is hydrolysable in vivo, that is under physiological conditions.
- a preferred group of triflusal or HTB carrier monomers for the preparation of the polymers of formula I are those that respond to formula II:
- Ri represents hydrogen or C ⁇ -4 alkyl
- R 2 represents -COCH3 or hydrogen
- X represents a group - (CH 2 CH 2 0) p -
- p represents an integer from 1 to 100.
- triflusal or HTB carrier monomers useful for preparing the polymers of formula I, are new and represent a further object of the present invention.
- this represents a residue of a second polymerizable monomer, so that when B is present in a polymer compound of formula I (i.e. when n is different from 0) the resulting compound is a copolymer, while when B is absent (that is, when n is 0) the resulting compound is a homopolymer.
- Examples of possible meanings for B include, among others, 2-hydroxyethyl methacrylate, methyl methacrylate, methyl acrylate, N-vinyl pyrrolidone, acrylic acid, methacrylic acid, acrylamide, N, N-dimethylacrylamide, vinyl acetate and 2- acid acrylamido-2-methylpropanesulfonic acid.
- monomer B may also be another polymerizable monomer carrying triflusal or HTB.
- a preferred group of compounds of the present invention are those polymeric compounds of formula I where the hydrolysable covalent bond through which the triflusal or HTB is attached is of the carboxylic ester type.
- Another preferred group of compounds are those compounds of formula I where n represents 0.
- Another preferred group of compounds are those compounds of formula I where n is other than 0.
- a more preferred group of compounds of formula I are those polymeric compounds that correspond to the relative formula:
- Ri represents hydrogen or C1-4 alkyl
- R 2 represents -COCH3 or hydrogen;
- X represents a group - (CH 2 CH 2 0) p -;
- p represents an integer from 1 to 100;
- B, m and n have the meaning described above.
- An especially preferred group of compounds of the present invention are those compounds of the formula where Ri represents methyl and p represents 1.
- a particularly preferred group of compounds are those compounds of the formula where Ri represents methyl; p represents 1 and n represents 0.
- Another particularly preferred group of compounds are those compounds of the formula where Ri represents methyl; p represents 1 and n is different from 0.
- Ri represents methyl
- p represents 1
- n is different from 0.
- B represents a residue of 2-hydroxyethyl methacrylate, methyl methacrylate, methyl acrylate, N-vinyl pyrrolidone, acrylic acid, methacrylic acid
- acrylamide, N, N-dirnetilacrilarr ⁇ ida, vinyl acetate and 2- acid acrylamido-2-methylpropanesulfonic acid and even more preferred are those compounds where B represents a residue of N, N-dirnerylacrylamide or 2-acrylamido-2-methylpropanesulfonic acid.
- the molecular weight of the polymeric compounds of the present invention can vary within a wide range, those polymeric compounds of formula I with an average molecular weight between 10,000 and 100,000 Daltons being preferred for application as a coating of non-biological materials.
- the polymeric compounds of formula I can be prepared by any of the known methods of radical polymerization.
- they can be prepared by solution polymerization of the desired monomer or monomers within a suitable solvent in the presence of a polymerization initiator. Said polymerization must be carried out in the absence of oxygen.
- any of the compounds described in the literature can be used for such purposes, for example, benzoflo peroxide, lauroyl peroxide, cumyl peroxide, butyl perbenzoate, 2,2'-azobisisobutyronitrile (AIBN) or 2,2 'acid -azobisisopentanoic, with benzoyl peroxide and 2,2'-azobisisobutyronitrile being preferred.
- the proportion of initiator to be used will depend on the desired molecular weight, and can easily be determined by one skilled in the art.
- the solvent used to carry out the polymerization may vary depending on the nature of the monomers used; A person skilled in the art can easily determine the most suitable solvent for each case.
- suitable solvents there may be mentioned dioxane, dimethylformamide, isopropanol, dioxane / water mixtures, chloroform, dimethylsulf oxide, acetone, acetone / dioxane mixtures and acetone / water mixtures, the use of solvents being preferred polar such as dimethylformamide or solvating solvents such as dioxane or dioxane / water mixtures rich in dioxane.
- reaction temperature will depend on the initiator used, being also a determining factor in the molecular weight of the resulting polymer system, as will be well known to those skilled in the art; In general, a temperature in the range of 50 to 70 ° C will be adequate.
- the required polymerization time is not too long, given the nature of the radical polymerization reactions and their condition of chain addition reactions; In general we have found that polymerization times of 6 to 24 hours are sufficient to achieve conversions of monomers to high polymer systems, although in some cases longer polymerization times may be necessary.
- the polymers of formula I are finally isolated by conventional methods, for example by precipitation in a suitable solvent such as for example ethanol, methanol, isopropanol, hexane, heptane or diethyl ether.
- a suitable solvent such as for example ethanol, methanol, isopropanol, hexane, heptane or diethyl ether.
- Triflusal or HTB-bearing acrylic or vinyl monomers can be prepared in general by covalent bond formation between a suitable acrylic or vinyl derivative and the triflusal or HTB derivative, or a reactive derivative thereof, following procedures analogous to those described in literature for the formation of such covalent bonds.
- the polymeric compounds of the present invention can be used for coating non-biological materials such as prostheses, stents and the like, thereby improving their properties.
- the coatings can be prepared in general by immersion of the surface to be coated in a diluted solution, for example 1-2% w / v, of the desired polymer in a suitable solvent such as, for example, dimethylformamide, ethanol, water / ethanol mixtures or dioxane / ethanol mixtures.
- Figure 1 shows the synthesis scheme of the triflusal carrier monomer described in example 1;
- Figure 2 shows the polymer synthesis scheme described in the example 2
- Figure 3 shows the NMR spectrum of ⁇ (3A) and 13 C (3B) of the polymer of example 2;
- Figure 4 shows the synthesis scheme of a poly [THEMA-co-DMA] copolymer described in example 3;
- Figure 5 shows the NMR spectrum of ⁇ (5A) and 13 C (5B) of polymer 3A described in example 3;
- Figure 6 shows the ⁇ NMR spectrum of polymer 3B described in example 3
- Figure 7 shows the ⁇ NMR spectrum of polymer 3C described in example 3;
- Figure 8 shows the ⁇ NMR spectrum of the 3D polymer described in example 3.
- Figure 9 shows the synthesis scheme of a poly [THEMA-co-AMPS] copolymer described in example 4.
- Figure 10 shows the NMR spectrum of ⁇ (10A) and 13 C (10B) of the polymer described in example 4;
- Figure 11 shows the release of HTB from polymer 3 A in rat plasma following the method described in example 5.
- the polymers were analyzed by nuclear magnetic resonance (NMR) spectroscopy of ⁇ and / or 13 C under the particular conditions described in each case.
- NMR nuclear magnetic resonance
- the myn molar fractions in the copolymers are determined by ⁇ NMR analysis. Due to the experimental error of the method, there may be deviations of up to 5% in the value of these molar fractions.
- the average molecular weights were determined by permeation chromatography on gels (Gel Permeation Chromatography, GPC) using a Perkin Elmer device consisting of an isocratic LC 250 pump and a detector of 200 series refractive index. The data is acquired with a PL-DCU (Polymer Laboratories). Samples are eluted using 3 series polystyrene-divinylbenzene pL-gel columns of 500, 10 4 and 10 5 ⁇ nominal pore size (Polymer Laboratories).
- This compound was prepared by polymerization of the triflusal carrier monomer obtained in example 1 (THEMA). The structure of this compound and its preparation are shown in the scheme of Fig. 2. 5 g of THEMA is dissolved in a pyrex bottle (obtained in the example
- the closed bottles are placed in a thermostated bath at 60 ° C for 24 hours.
- the polymer is precipitated in excess of ethanol; to precipitate 5 g of polymer, 500 mL of ethanol are used, on which the polymer solution is added dropwise. This stage is carried out in an ice bath.
- the solution is kept under constant stirring for 4 h and then filtered under vacuum.
- the precipitate obtained is washed several times with ethanol and filtered again, and then dried in a high vacuum oven until constant weighing.
- the reaction yield is 90%.
- Example 3 Synthesis of copolymers from THEMA and N, N-dimethylacrylamide (DMA) with different m / n molar fractions (pol THEMA-co-DMAP The structure of these copolymers and their synthesis scheme are shown in the scheme of Fig. 4.
- the preparation of a representative THEMA-DMA copolymer is carried out as follows: 1 g of THEMA (obtained in example 1) and 1 g of DMA are dissolved in
- polymer 3A (hereinafter referred to as polymer 3A) is 52% by weight THEMA and a molar fraction m / n of 0.18 / 0.82.
- the GPC determination of the average molecular weight of this polymer gave a value of 33000 Daltons, with a polydispersity index of 2.4.
- Example 4 Synthesis of a copolymer from THEMA and 2-acrylamido-2-methylpropanesulfonic acid (AMPS) (poly-THEMA-co-AMPS1)
- the closed bottle is placed in a thermostated bath at 50 ° C for 24 hours, after this time part of the solvent is evaporated in the rotary evaporator and then the polymer is precipitated with 100 mL of diethyl ether.
- the solution is kept under constant stirring for 1 h and then the solvent is removed in the rotary evaporator.
- the residue is then dissolved in 10 mL of distilled water, and lyophilized. The yield of this process is 100%.
- Example 5 Release test of the antiaggregant compound contained in a polymer of formula I in rat plasma
- the release of the antiaggregant compound from the polymers of the present invention can be evaluated using an in vitro assay consisting of incubating at 37 ° C and with constant stirring, rat plasma to which a solution of the desired polymer is added and determined at different times. HPLC drug release. In parallel, and in order to check the linearity and accuracy of the method, the same test is carried out but with drug solutions prepared directly.
- a) Obtaining the plasma To obtain the rat plasma, the cardiac puncture technique is used, which consists of introducing the animal into a previously saturated chamber of dietary ether and waiting for the animal to reach the state of anesthesia, at which time It is placed in the ventral position and fixed to a table to perform a puncture through the intercostal spaces until reaching the heart.
- the pulverized polymer is dissolved in methanol and 0.96 g / mL concentration solutions are prepared, equivalent to a total HTB concentration of 1.4 mM.
- concentrations of HTB used for this are: 1.25 mM, 1.5 mM, 6.2 mM and 9.3 mM.
- the rat plasma is divided into 0.2 mL volumes distributed in polypropylene tubes, to each of which 10 ⁇ L of the corresponding polymer solution is added.
- the battery of tubes is introduced in a 37 ° C bath and with constant agitation and samples are taken at different times, which are analyzed by HPLC, using the following conditions: - Waterspane C-18 column ⁇ Boundapak 3.9x300 mm;
- Example 6 Example of preparation of a coating with a polymer of formula I
- Example 7 Evaluation of the thrombogenic properties of a non-biological material coated with a polymer of the invention
- the effect of the application of a polymer of the invention as a coating of a non-biological material on the thrombogenic properties thereof can be evaluated in vitro by the study of platelet aggregation on the material coated with a polymer of the invention compared to that observed in said uncoated material;
- the analysis of platelet aggregation can be performed by determining the amount of platelets retained on the material or by scanning electron microscopy (SEM).
- platelet rich plasma from sheep's blood obtained from centrifugation of 40 L of blood at 1500 rpm for 10 min is used. After this time, the supernatant is removed and a platelet count is performed on a Serono-3000 hematological counter.
- the non-biological material used in the experiment are vascular grafts of Goretex ® of 4 mm internal diameter.
- a group of prostheses coated with a polymer and a control group are used.
- the prostheses are mounted on sowing chambers and 100 ⁇ L of PRP is added.
- the chambers are incubated at 37 ° C in a culture oven (5% C02) during different study times.
- the prostheses are washed three times with MEM (Minimal Essential Medium) to eliminate the non-retained platelets and the number of platelets retained in the prostheses is compared compared to the control group indirectly through the count of the number of platelets recovered in each of the times.
- the samples are fixed with glutaraldehyde, washed with buffer solution of pH 7.4, dehydrated in gradual series of acetone and metallized with gold / shovel for study by MEB using a Zeiss 950 DSM scanning electron microscope.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Paints Or Removers (AREA)
- Materials For Medical Uses (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR0013760-0A BR0013760A (pt) | 1999-09-03 | 2000-09-01 | Sistemas poliméricos biocompatìveis carregando triflusal ou htb |
US10/070,244 US6979465B1 (en) | 1999-09-03 | 2000-09-01 | Biocompatible polymer systems carrying triflusal or HTB |
AU68436/00A AU6843600A (en) | 1999-09-03 | 2000-09-01 | New biocompatible polymer systems carrying triflusal or htb |
MXPA02002288A MXPA02002288A (es) | 1999-09-03 | 2000-09-01 | Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb. |
EP00956531A EP1210954B1 (en) | 1999-09-03 | 2000-09-01 | New biocompatible polymer systems carrying triflusal or htb |
DE60019766T DE60019766T2 (de) | 1999-09-03 | 2000-09-01 | Triflusal oder htb tragende biokompatible polymersysteme |
JP2001521365A JP2003508592A (ja) | 1999-09-03 | 2000-09-01 | トリフルサルまたはhtbを有する新規な生物相容性重合体系 |
DK00956531T DK1210954T3 (da) | 1999-09-03 | 2000-09-01 | Nye biokompatible polymersystemer, der bærer triflusal eller HTB |
CA002383780A CA2383780A1 (en) | 1999-09-03 | 2000-09-01 | New biocompatible polymeric systems carrying triflusal or htb |
SI200030675T SI1210954T1 (es) | 1999-09-03 | 2000-09-01 | |
ES00956531T ES2241641T3 (es) | 1999-09-03 | 2000-09-01 | Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb. |
AT00956531T ATE294001T1 (de) | 1999-09-03 | 2000-09-01 | Triflusal oder htb tragende biokompatible polymersysteme |
NO20021027A NO20021027L (no) | 1999-09-03 | 2002-03-01 | Biokompatible polymersystemer som baerer for trifusal eller HTB |
US11/267,209 US7445789B2 (en) | 1999-09-03 | 2005-11-07 | Biocompatible polymeric systems carrying triflusal or HTB |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009902013A ES2154242B1 (es) | 1999-09-03 | 1999-09-03 | Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb. |
ESP9902013 | 1999-09-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10070244 A-371-Of-International | 2000-09-01 | ||
US11/267,209 Division US7445789B2 (en) | 1999-09-03 | 2005-11-07 | Biocompatible polymeric systems carrying triflusal or HTB |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001017578A1 true WO2001017578A1 (es) | 2001-03-15 |
Family
ID=8309883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2000/000335 WO2001017578A1 (es) | 1999-09-03 | 2000-09-01 | Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb |
Country Status (17)
Country | Link |
---|---|
US (2) | US6979465B1 (es) |
EP (1) | EP1210954B1 (es) |
JP (1) | JP2003508592A (es) |
KR (1) | KR100838545B1 (es) |
AR (1) | AR033343A1 (es) |
AT (1) | ATE294001T1 (es) |
AU (1) | AU6843600A (es) |
BR (1) | BR0013760A (es) |
CA (1) | CA2383780A1 (es) |
DE (1) | DE60019766T2 (es) |
DK (1) | DK1210954T3 (es) |
ES (2) | ES2154242B1 (es) |
MX (1) | MXPA02002288A (es) |
NO (1) | NO20021027L (es) |
PT (1) | PT1210954E (es) |
TR (1) | TR200200591T2 (es) |
WO (1) | WO2001017578A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014787A1 (en) * | 2005-09-21 | 2007-02-08 | Palau Pharma, S.A. | Triflusal-containing polymers for stent coating |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4096252A (en) * | 1976-06-10 | 1978-06-20 | J. Uriach & Cia S.A. | 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents |
GB2167665A (en) * | 1984-12-04 | 1986-06-04 | Univ Liverpool | Platelet aggregation inhibitor for use in polymeric surgical devices |
EP0351314A2 (en) * | 1988-07-11 | 1990-01-17 | Terumo Kabushiki Kaisha | Medical material and medical implement |
EP0596615A1 (en) * | 1992-10-30 | 1994-05-11 | Medtronic, Inc. | Articles having bioactive surfaces |
WO1997041164A1 (en) * | 1996-04-30 | 1997-11-06 | Ajay Kumar Luthra | Non-thrombogenic and anti-thrombogenic polymers |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0221875A (ja) * | 1988-07-11 | 1990-01-24 | Terumo Corp | 医療用材料ならびに医療用器具 |
ES2136581B1 (es) * | 1998-05-27 | 2000-09-16 | Uriach & Cia Sa J | Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb. |
-
1999
- 1999-09-03 ES ES009902013A patent/ES2154242B1/es not_active Expired - Fee Related
-
2000
- 2000-08-18 AR ARP000104307A patent/AR033343A1/es active IP Right Grant
- 2000-09-01 WO PCT/ES2000/000335 patent/WO2001017578A1/es active IP Right Grant
- 2000-09-01 AT AT00956531T patent/ATE294001T1/de not_active IP Right Cessation
- 2000-09-01 DK DK00956531T patent/DK1210954T3/da active
- 2000-09-01 KR KR1020027002856A patent/KR100838545B1/ko not_active IP Right Cessation
- 2000-09-01 US US10/070,244 patent/US6979465B1/en not_active Expired - Fee Related
- 2000-09-01 JP JP2001521365A patent/JP2003508592A/ja active Pending
- 2000-09-01 PT PT00956531T patent/PT1210954E/pt unknown
- 2000-09-01 DE DE60019766T patent/DE60019766T2/de not_active Expired - Lifetime
- 2000-09-01 BR BR0013760-0A patent/BR0013760A/pt not_active IP Right Cessation
- 2000-09-01 ES ES00956531T patent/ES2241641T3/es not_active Expired - Lifetime
- 2000-09-01 AU AU68436/00A patent/AU6843600A/en not_active Abandoned
- 2000-09-01 MX MXPA02002288A patent/MXPA02002288A/es active IP Right Grant
- 2000-09-01 EP EP00956531A patent/EP1210954B1/en not_active Expired - Lifetime
- 2000-09-01 TR TR2002/00591T patent/TR200200591T2/xx unknown
- 2000-09-01 CA CA002383780A patent/CA2383780A1/en not_active Abandoned
-
2002
- 2002-03-01 NO NO20021027A patent/NO20021027L/no not_active Application Discontinuation
-
2005
- 2005-11-07 US US11/267,209 patent/US7445789B2/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4096252A (en) * | 1976-06-10 | 1978-06-20 | J. Uriach & Cia S.A. | 4-Trifluoromethylbenzoic acid derivatives as thromboembolic agents |
GB2167665A (en) * | 1984-12-04 | 1986-06-04 | Univ Liverpool | Platelet aggregation inhibitor for use in polymeric surgical devices |
EP0351314A2 (en) * | 1988-07-11 | 1990-01-17 | Terumo Kabushiki Kaisha | Medical material and medical implement |
EP0596615A1 (en) * | 1992-10-30 | 1994-05-11 | Medtronic, Inc. | Articles having bioactive surfaces |
WO1997041164A1 (en) * | 1996-04-30 | 1997-11-06 | Ajay Kumar Luthra | Non-thrombogenic and anti-thrombogenic polymers |
Non-Patent Citations (1)
Title |
---|
RODRIGUEZ G. ET AL.: "New resorbable polymeric systems with antithrombogenic activity", J. MATER. SCI. MATER. MED., vol. 10, no. 12, 1999, pages 873 - 878, XP001000029 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007014787A1 (en) * | 2005-09-21 | 2007-02-08 | Palau Pharma, S.A. | Triflusal-containing polymers for stent coating |
EP1767552A1 (en) * | 2005-09-21 | 2007-03-28 | Palau Pharma, S.A. | Triflusal-containing polymers for stent coating |
Also Published As
Publication number | Publication date |
---|---|
NO20021027D0 (no) | 2002-03-01 |
AR033343A1 (es) | 2003-12-17 |
ES2154242B1 (es) | 2001-10-16 |
ES2154242A1 (es) | 2001-03-16 |
PT1210954E (pt) | 2005-07-29 |
DE60019766D1 (de) | 2005-06-02 |
ATE294001T1 (de) | 2005-05-15 |
KR20020059387A (ko) | 2002-07-12 |
NO20021027L (no) | 2002-04-10 |
KR100838545B1 (ko) | 2008-06-17 |
US6979465B1 (en) | 2005-12-27 |
US20060067955A1 (en) | 2006-03-30 |
ES2241641T3 (es) | 2005-11-01 |
AU6843600A (en) | 2001-04-10 |
US7445789B2 (en) | 2008-11-04 |
EP1210954A1 (en) | 2002-06-05 |
EP1210954B1 (en) | 2005-04-27 |
JP2003508592A (ja) | 2003-03-04 |
MXPA02002288A (es) | 2002-07-30 |
DK1210954T3 (da) | 2005-08-15 |
TR200200591T2 (tr) | 2002-06-21 |
BR0013760A (pt) | 2002-07-02 |
DE60019766T2 (de) | 2006-01-19 |
CA2383780A1 (en) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6251964B1 (en) | Biocompatible compositions | |
JP2890316B2 (ja) | 生体適合性医療デバイス用材料 | |
JP4961133B2 (ja) | 医療用材料 | |
JP2870727B2 (ja) | 2−メタクリロイルオキシエチルホスホリルコリン共重合体 | |
CN104039949B (zh) | 细胞粘附抑制剂 | |
EP0714417B1 (en) | Polymer surface coatings | |
US8163302B2 (en) | Methods of making and using surfactant polymers | |
JP7158993B2 (ja) | ホスホリルコリン基含有共重合体、および生体用医療基材 | |
JP4219154B2 (ja) | 血液適合性高分子を用いた医療用器具 | |
US6294614B1 (en) | Modified polymers containing poly(2-hydroxyethyl(meth)acrylate segment in the molecule | |
US8236913B2 (en) | (Meth)acrylate copolymer, a method for producing the same and a medical device | |
ES2241641T3 (es) | Nuevos sistemas polimericos biocompatibles portadores de triflusal o htb. | |
Rodri´ guez et al. | New resorbable polymeric systems with antithrombogenic activity | |
JP2004298223A (ja) | 生体適合性材料 | |
EP3269747B1 (en) | Antithrombotic block copolymer | |
JPH07268038A (ja) | ホスホリルコリン基又はその誘導体基含有共重合体、その製造法及び抗血栓性材料 | |
WO2023013410A1 (ja) | 高分子組成物 | |
KR100431245B1 (ko) | 항혈전성 삼성분계 공중합체 | |
JP2001000533A (ja) | 生体適合性医用材料 | |
CN116410423A (zh) | 嵌段共聚物及其制备方法、涂料组合物、抗吸附涂层 | |
JPH10165494A (ja) | 抗血栓性組成物および医用材料 | |
JP2012029830A (ja) | ヘパリンコーティング剤及び医療用具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000956531 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2383780 Country of ref document: CA Ref document number: PA/a/2002/002288 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027002856 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2001 521365 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/00591 Country of ref document: TR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000956531 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10070244 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027002856 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2002 200201058 Country of ref document: RO Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000956531 Country of ref document: EP |